{"url_path":"/sec/rytm/8-k/2026-06-25/item-3","section_key":"item-3","section_title":"Item 3 Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1649904/0001628280-26-045569-index.html","accession_number":"0001628280-26-045569","cik":"0001649904","ticker":"RYTM","issuer_name":"RHYTHM PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1649904/0001628280-26-045569-index.html","primary_entity_key":"0001649904","primary_entity_name":"RHYTHM PHARMACEUTICALS, INC."},"word_count":98,"has_tables":true,"body_markdown":"Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers.\n\nVotes FORVotes AGAINSTVotes ABSTAINEDBroker Non-Votes\n\n50,368,65911,467,15736,6822,273,648\n\nBased on the foregoing votes, David W. J. McGirr and David P. Meeker, MD were elected as Class III Directors, and Items 2 and 3 were approved.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nRHYTHM PHARMACEUTICALS, INC.\n\nDate: June 25, 2026By:/s/ Hunter Smith\n\nHunter Smith\n\nChief Financial Officer"}